Doheny Asset Management CA Takes Position in FibroGen, Inc. (NASDAQ:FGEN)

Doheny Asset Management CA bought a new position in shares of FibroGen, Inc. (NASDAQ:FGEN) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 53,570 shares of the biopharmaceutical company’s stock, valued at approximately $48,000. Doheny Asset Management CA owned 0.05% of FibroGen as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Acadian Asset Management LLC grew its position in shares of FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after purchasing an additional 860,854 shares during the last quarter. Franklin Street Advisors Inc. NC acquired a new position in FibroGen in the 2nd quarter valued at $89,000. Accel Wealth Management increased its position in FibroGen by 117.5% during the 2nd quarter. Accel Wealth Management now owns 95,600 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 51,645 shares during the period. Alpine Global Management LLC bought a new position in FibroGen during the 1st quarter worth $25,000. Finally, Delap Wealth Advisory LLC acquired a new stake in shares of FibroGen during the first quarter worth $27,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on FGEN shares. William Blair reissued a “market perform” rating on shares of FibroGen in a report on Monday, June 3rd. StockNews.com started coverage on FibroGen in a research note on Tuesday, September 3rd. They issued a “hold” rating for the company.

FibroGen Stock Performance

Shares of FGEN stock opened at $0.39 on Tuesday. FibroGen, Inc. has a fifty-two week low of $0.33 and a fifty-two week high of $2.93. The stock’s fifty day moving average price is $0.66 and its two-hundred day moving average price is $1.19. The company has a market cap of $39.64 million, a PE ratio of -0.16 and a beta of 0.69.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.09. The firm had revenue of $50.64 million during the quarter, compared to the consensus estimate of $33.00 million. During the same quarter in the previous year, the company posted ($0.65) earnings per share. On average, equities analysts predict that FibroGen, Inc. will post -0.91 EPS for the current fiscal year.

Insider Buying and Selling at FibroGen

In other FibroGen news, insider Deyaa Adib purchased 22,123 shares of the business’s stock in a transaction dated Wednesday, June 12th. The shares were bought at an average price of $1.17 per share, for a total transaction of $25,883.91. Following the completion of the acquisition, the insider now owns 82,123 shares in the company, valued at $96,083.91. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.98% of the company’s stock.

FibroGen Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.